176 related articles for article (PubMed ID: 30814645)
1. Prognostic impact of ATM mutations in patients with metastatic colorectal cancer.
Randon G; Fucà G; Rossini D; Raimondi A; Pagani F; Perrone F; Tamborini E; Busico A; Peverelli G; Morano F; Niger M; Antista M; Corallo S; Saggio S; Borelli B; Zucchelli G; Milione M; Pruneri G; Di Bartolomeo M; Falcone A; de Braud F; Cremolini C; Pietrantonio F
Sci Rep; 2019 Feb; 9(1):2858. PubMed ID: 30814645
[TBL] [Abstract][Full Text] [Related]
2. Ataxia Telangiectasia Mutated Protein Loss and Benefit From Oxaliplatin-based Chemotherapy in Colorectal Cancer.
Sundar R; Miranda S; Rodrigues DN; Chénard-Poirier M; Dolling D; Clarke M; Figueiredo I; Bertan C; Yuan W; Ferreira A; Chistova R; Boysen G; Perez DR; Tunariu N; Mateo J; Wotherspoon A; Chau I; Cunningham D; Valeri N; Carreira S; de Bono J
Clin Colorectal Cancer; 2018 Dec; 17(4):280-284. PubMed ID: 30042009
[TBL] [Abstract][Full Text] [Related]
3. Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie).
Huemer F; Thaler J; Piringer G; Hackl H; Pleyer L; Hufnagl C; Weiss L; Greil R
BMC Cancer; 2018 Jan; 18(1):11. PubMed ID: 29298682
[TBL] [Abstract][Full Text] [Related]
4. Association of Tumor Protein p53 and Ataxia-Telangiectasia Mutated Comutation With Response to Immune Checkpoint Inhibitors and Mortality in Patients With Non-Small Cell Lung Cancer.
Chen Y; Chen G; Li J; Huang YY; Li Y; Lin J; Chen LZ; Lu JP; Wang YQ; Wang CX; Pan LK; Xia XF; Yi X; Chen CB; Zheng XW; Guo ZQ; Pan JJ
JAMA Netw Open; 2019 Sep; 2(9):e1911895. PubMed ID: 31539077
[TBL] [Abstract][Full Text] [Related]
5. BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis.
Cremolini C; Di Bartolomeo M; Amatu A; Antoniotti C; Moretto R; Berenato R; Perrone F; Tamborini E; Aprile G; Lonardi S; Sartore-Bianchi A; Fontanini G; Milione M; Lauricella C; Siena S; Falcone A; de Braud F; Loupakis F; Pietrantonio F
Ann Oncol; 2015 Oct; 26(10):2092-7. PubMed ID: 26153495
[TBL] [Abstract][Full Text] [Related]
6. Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer.
Schirripa M; Cremolini C; Loupakis F; Morvillo M; Bergamo F; Zoratto F; Salvatore L; Antoniotti C; Marmorino F; Sensi E; Lupi C; Fontanini G; De Gregorio V; Giannini R; Basolo F; Masi G; Falcone A
Int J Cancer; 2015 Jan; 136(1):83-90. PubMed ID: 24806288
[TBL] [Abstract][Full Text] [Related]
7. ATM mutations as an independent prognostic factor and potential biomarker for immune checkpoint therapy in endometrial cancer.
Sun L; Wang RC; Zhang Q; Guo LL
Pathol Res Pract; 2020 Aug; 216(8):153032. PubMed ID: 32703496
[TBL] [Abstract][Full Text] [Related]
8. Identification of ATM Mutation as a Potential Prognostic Biomarker for Immune Checkpoint Inhibitors Therapy.
Cui S; Chen T; Zhao Y; Xiao Z; Liu M; Huang X; Cao S; Zhou R; Li Y; Huo X; Wang N
Curr Cancer Drug Targets; 2024; 24(5):501-509. PubMed ID: 38804343
[TBL] [Abstract][Full Text] [Related]
9. KRAS mutations are associated with inferior clinical outcome in patients with metastatic colorectal cancer, but are not predictive for benefit with cediranib.
Smith JC; Brooks L; Hoff PM; McWalter G; Dearden S; Morgan SR; Wilson D; Robertson JD; Jürgensmeier JM
Eur J Cancer; 2013 Jul; 49(10):2424-32. PubMed ID: 23510802
[TBL] [Abstract][Full Text] [Related]
10. ATM mutations and E-cadherin expression define sensitivity to EGFR-targeted therapy in colorectal cancer.
Geißler AL; Geißler M; Kottmann D; Lutz L; Fichter CD; Fritsch R; Weddeling B; Makowiec F; Werner M; Lassmann S
Oncotarget; 2017 Mar; 8(10):17164-17190. PubMed ID: 28199979
[TBL] [Abstract][Full Text] [Related]
11. The enrichment of Fanconi anemia/homologous recombination pathway aberrations in ATM/ATR-mutated NSCLC was accompanied by unique molecular features and poor prognosis.
Wei W; Shi F; Xu Y; Jiao Y; Zhang Y; Ou Q; Wu X; Yang L; Lai J
J Transl Med; 2023 Dec; 21(1):874. PubMed ID: 38041093
[TBL] [Abstract][Full Text] [Related]
12. KRAS mutations in tumor tissue and plasma by different assays predict survival of patients with metastatic colorectal cancer.
Xu JM; Liu XJ; Ge FJ; Lin L; Wang Y; Sharma MR; Liu ZY; Tommasi S; Paradiso A
J Exp Clin Cancer Res; 2014 Dec; 33(1):104. PubMed ID: 25491325
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of ATM mutations in chronic lymphocytic leukemia: A meta-analysis.
Baghaei Vaji F; Boroumand Nasr A; Rezvani A; Ayatollahi H; Goudarzi S; Lavasani S; Bagheri R
Leuk Res; 2021 Dec; 111():106729. PubMed ID: 34735935
[TBL] [Abstract][Full Text] [Related]
14. Ataxia-telangiectasia-mutated protein expression with microsatellite instability in gastric cancer as prognostic marker.
Kim JW; Im SA; Kim MA; Cho HJ; Lee DW; Lee KH; Kim TY; Han SW; Oh DY; Lee HJ; Kim TY; Yang HK; Kim WH; Bang YJ
Int J Cancer; 2014 Jan; 134(1):72-80. PubMed ID: 23649938
[TBL] [Abstract][Full Text] [Related]
15. Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer.
Margonis GA; Buettner S; Andreatos N; Kim Y; Wagner D; Sasaki K; Beer A; Schwarz C; Løes IM; Smolle M; Kamphues C; He J; Pawlik TM; Kaczirek K; Poultsides G; Lønning PE; Cameron JL; Burkhart RA; Gerger A; Aucejo FN; Kreis ME; Wolfgang CL; Weiss MJ
JAMA Surg; 2018 Jul; 153(7):e180996. PubMed ID: 29799910
[TBL] [Abstract][Full Text] [Related]
16. G12V and G12A KRAS mutations are associated with poor outcome in patients with metastatic colorectal cancer treated with bevacizumab.
Fiala O; Buchler T; Mohelnikova-Duchonova B; Melichar B; Matejka VM; Holubec L; Kulhankova J; Bortlicek Z; Bartouskova M; Liska V; Topolcan O; Sedivcova M; Finek J
Tumour Biol; 2016 May; 37(5):6823-30. PubMed ID: 26662311
[TBL] [Abstract][Full Text] [Related]
17. Impact of Metastasectomy in the Multimodality Approach for
Johnson B; Jin Z; Truty MJ; Smoot RL; Nagorney DM; Kendrick ML; Kipp BR; Grothey A
Oncologist; 2018 Jan; 23(1):128-134. PubMed ID: 28904173
[TBL] [Abstract][Full Text] [Related]
18. ATM and p53 combined analysis predicts survival in glioblastoma multiforme patients: A clinicopathologic study.
Romano FJ; Guadagno E; Solari D; Borrelli G; Pignatiello S; Cappabianca P; Del Basso De Caro M
J Cell Biochem; 2018 Jun; 119(6):4867-4877. PubMed ID: 29369420
[TBL] [Abstract][Full Text] [Related]
19. An Analysis of Relationship Between RAS Mutations and Prognosis of Primary Tumour Resection for Metastatic Colorectal Cancer Patients.
Liang L; Tian J; Yu Y; Wang Z; Peng K; Liu R; Wang Y; Xu X; Li H; Zhuang R; Cui Y; Zhu C; Liu T
Cell Physiol Biochem; 2018; 50(2):768-782. PubMed ID: 30308491
[TBL] [Abstract][Full Text] [Related]
20. Spatio-temporal mutation profiles of case-matched colorectal carcinomas and their metastases reveal unique de novo mutations in metachronous lung metastases by targeted next generation sequencing.
Kovaleva V; Geissler AL; Lutz L; Fritsch R; Makowiec F; Wiesemann S; Hopt UT; Passlick B; Werner M; Lassmann S
Mol Cancer; 2016 Oct; 15(1):63. PubMed ID: 27756406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
